Medivation

"People thought we were a little crazy," admits Lynn Seely, discussing her company's goal of finding a better way to treat prostate cancer. The chief medical officer of the San Francisco–based pharma company embraced the challenge because one in six U.S. men will be diagnosed with the disease, and the long-common treatment—androgen suppression therapy—can lead to depression, loss of libido, and worse.